What is Isogenica?
Isogenica operates at the intersection of biotechnology and pharmaceutical research, specializing in the discovery and engineering of VHH single-domain antibodies. The company distinguishes itself through the deployment of the world's largest synthetic VHH libraries, integrated with its proprietary CIS Display technology. This technical infrastructure allows Isogenica to provide bespoke antibody discovery services that significantly compress development timelines for its partners. By focusing on high-specificity and high-affinity molecules, the firm serves as a vital extension for organizations working in complex therapeutic areas, including antibody drug conjugates, cell therapy, and immuno-oncology. Their collaborative business model is designed to strengthen the intellectual property portfolios of their clients while accelerating the transition from discovery to clinical application.
How much funding has Isogenica raised?
Isogenica has raised a total of $646K across 1 funding round:
Unspecified
$646K
Unspecified (2012): $646K, investors not publicly disclosed
Key Investors in Isogenica
Undisclosed Investor
An institutional partner providing strategic capital to support the advancement of proprietary antibody discovery platforms.
Undisclosed Investor
A private equity or venture entity focused on long-term growth within the biotechnology and life sciences sector.
Undisclosed Investor
A strategic backer specializing in early-to-mid stage therapeutic technology development and intellectual property commercialization.
What's next for Isogenica?
With the recent capital injection, Isogenica is well-positioned to expand its footprint in the immuno-oncology sector. The strategic roadmap likely involves scaling its synthetic library capabilities and deepening its integration into the R&D pipelines of major pharmaceutical entities. As the industry shifts toward more targeted, modular therapeutic formats, Isogenica's focus on VHH single-domain antibodies provides a distinct competitive advantage. Future growth will likely be driven by the continued optimization of their CIS Display platform and the pursuit of high-value partnerships that leverage their unique expertise in antibody engineering to solve complex biological challenges.
See full Isogenica company page
